Matinas BioPharma Holdings (MTNB) Enterprise Value (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Enterprise Value of -$2.4 million for Q1 2026, up 64.9% year-over-year from -$1.5 million in Q1 2025, and up 39.54% quarter-over-quarter from -$4.0 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Enterprise Value (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Enterprise Value for 14 consecutive years, with -$2.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 64.9% year-over-year to -$2.4 million; the TTM figure through Mar 2026 stood at -$2.4 million (up 64.9% YoY), while the FY2025 annual figure was -$4.0 million, up 44.79% from the prior year.
- Enterprise Value advanced to -$2.4 million in Q1 2026 per MTNB's latest filing, from -$4.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$1.1 million in Q1 2024 and bottomed at -$43.8 million in Q1 2022.
- Historically, Enterprise Value has averaged -$12.4 million across 5 years, with a median of -$6.6 million in 2025.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 86.79% — and 2025, when it plunged 522.12%.
- Matinas BioPharma Holdings' Enterprise Value stood at -$6.9 million in 2022, then advanced by 29.69% to -$4.8 million in 2023, then tumbled by 51.62% to -$7.3 million in 2024, then surged by 44.79% to -$4.0 million in 2025, then surged by 39.54% to -$2.4 million in 2026.
- Business Quant data shows MTNB's Enterprise Value at -$2.4 million in Q1 2026, -$4.0 million in Q4 2025, and -$5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | -811,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -811,000.00 |
| Mar 31, 2026 | -2.45 Mn |
| Dec 31, 2025 | -4.05 Mn |
| Sep 30, 2025 | -5.49 Mn |
| Jun 30, 2025 | -6.58 Mn |
| Mar 31, 2025 | -6.97 Mn |
| Dec 31, 2024 | -7.33 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -4.27 Mn |
| Mar 31, 2024 | -1.12 Mn |
| Dec 31, 2023 | -4.84 Mn |
| Sep 30, 2023 | -6.46 Mn |
| Jun 30, 2023 | -22.51 Mn |
| Mar 31, 2023 | -5.79 Mn |
| Dec 31, 2022 | -6.88 Mn |
| Sep 30, 2022 | -33.05 Mn |
| Jun 30, 2022 | -38.50 Mn |
| Mar 31, 2022 | -43.83 Mn |
| Dec 31, 2021 | -49.62 Mn |
| Sep 30, 2021 | -53.82 Mn |